Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Kageji, Teruyoshi*; Mizobuchi, Yoshifumi*; Nagahiro, Shinji*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.60 - 61, 2006/10
We compared and evaluated boron neutron capture therapy (BNCT) radiation dose between gold wire measurement and JAERI Computational Dosimetry System (JCDS). Gold wire analysis demonstrates the actual BNCT dose though it dose not reflect the real the maximum and minimum dose in tumor tissue. We can conclude that JCDS is precise and high-reliable dose planning system for BNCT.
Kageji, Teruyoshi*; Mizobuchi, Yoshifumi*; Nagahiro, Shinji*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.62 - 63, 2006/10
We compared and evaluated BNCT radiation dose using JAERI Computational Dosimetry System (JCDS) between BSH-base intra-operative BNCT and BSH, BPA-based non-operative BNCT. In comparison of BNCT radiation dose, BSH-based intra-operative BNCT was 1.4-2.1 times higher than BSH, BPA-basednon-operative BNCT.
Kageji, Teruyoshi*; Mizobuchi, Yoshifumi*; Nagahiro, Shinji*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.35 - 36, 2006/10
We analyzed the correlation between boron neutron capture therapy (BNCT) radiation dose and histopathological findings of autopsy or salvage surgery. For the complete remission of glioblastoma (GBM) after BNCT, minimum gross tumor volume (GTV) and clinical target volume (CTV) dose should be 65 and 45 Gy-Eq as a JAERI Computational Dosimetry System (JCDS) dose.
Kageji, Teruyoshi*; Nagahiro, Shinji*; Matsuzaki, Kazuhito*; Mizobuchi, Yoshifumi*; Toi, Hiroyuki*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
International Journal of Radiation Oncology, Biology, Physics, 65(5), p.1446 - 1455, 2006/08
Times Cited Count：32 Percentile：64.30(Oncology)Clinical trials for boron neutron capture therapy (BNCT) for malignant glioma were performed with thermal-epithermal mixed neutron beam generated by JRR-4. The first protocol (P1998) prescribed a maximal gross tumor volume (GTV) dose of 15 Gy since 1998, and then the protocol was applied to 8 patients. In 2001, a dose-escalated protocol (P2001) was introduced, which prescribed a maximal vascular volume dose of 15 Gy, or alternatively, a clinical target volume (CTV) dose of 18 Gy, the protocol was applied to 11 patients. The GTV and CTV doses in P2001 were 1.1-1.3 times greater than those in P1998. The maximal vascular volume dose of those with acute radiation injury was 15.8 Gy. The mean GTV and CTV dose in long-term survivors with glioblastoma was 26.4 and 16.5 Gy, respectively. A statistically significant correlation between the GTV dose and median survival time was found. In the 11 glioblastoma patients in P2001, the median survival time was 19.5 months and 1- and 2-year survival rate was 60.6 % and 37.9 %, respectively. Dose escalation contributed to the improvement in clinical outcome. To avoid radiation injury, the maximal vascular volume dose should be 
12 Gy. For long-term survival in patients with glioblastoma after boron neutron capture therapy, the optimal mean dose of the GTV and CTV was 26 and 16 Gy, respectively. This report introduces principle of BNCT and the activities for the BNCT clinical trials using JRR-4 in JAEA, and the clinical outcomes of the trials under the protocols and radiation injury in the irradiation are described.
Kageji, Teruyoshi*; Nagahiro, Shinji*; Mizobuchi, Yoshifumi*; Toi, Hiroyuki*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
Applied Radiation and Isotopes, 61(5), p.1063 - 1067, 2004/11
Times Cited Count：10 Percentile：54.01(Chemistry, Inorganic & Nuclear)no abstracts in English
